Mechanism of pachymic acid in the treatment of gastric cancer based on network pharmacology and experimental verification

Figure 2 Prediction of core targets. A: Number of gastric cancer (GC) targets and pachymic acid (PA) targets; B: Venn diagram of intersection of target PA targets in GC; C: Protein-protein interaction (PPI) network diagram of intersection targets; D: Degree values of core targets; E: PPI network graph sorted by degree value, and core targets were screened according to degree value greater than 10. SRC: Proto-oncogene tyrosine-protein kinase Src; MAPK1: Mitogen-activated protein kinase 1; PI3KR1: Phosphatidylinositol 3-kinase regulatory subunit alpha; HSP90AA1: Heat shock protein 90-alpha; PTPN11: Tyrosine-protein phosphatase non-receptor type 11; GRB2: Growth factor receptor-bound protein 2; RXRA: Retinoic acid receptor RXR-alpha; MAPK14: Mitogen-activated protein kinase 14; EGFR: Epidermal growth factor receptor; ESR1: Estrogen receptor; JAK2: Tyrosine-protein kinase JAK2; PRKACA: cAMP-dependent protein kinase catalytic subunit alpha; NR3C1: Glucocorticoid receptor; STAT1: Signal transducer and activator of transcription 1-alpha/beta; RARA: Retinoic acid receptor alpha; IGF1R: Insulin-like growth factor 1 receptor; HCK: Tyrosine-protein kinase HCK; KDR: Vascular endothelial growth factor receptor 2; CTNNA1: Catenin alpha-1; AR: Androgen receptor; CASP3: Caspase-3; SYK: Syrosine-protein kinase SYK; IL2: Interleukin-2.